1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 Education & Student Services, Faculty Service, Faculty of Health and Medical Sciences, Københavns Universitet3 Secretariat - Examinations administration, Faculty Service, Faculty of Health and Medical Sciences, Københavns Universitet4 unknown5 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet6 Secretariat - Examinations administration, Faculty Service, Faculty of Health and Medical Sciences, Københavns Universitet
INTRODUCTION: The metabolic bone disease osteoporosis is a growing health and health-economic problem worldwide. Bisphosphonates are the most widely used antiresorptive medication and the de facto gold standard in fracture prophylaxis all over the world, in conjunction with calcium and vitamin D supplementation. Several new medications for the treatment of postmenopausal osteoporosis are in the pipeline. AREAS COVERED: The authors present the most recent studies on new and current antiresorptive as well as anabolic drugs. Specifically, the authors present the current knowledge on drugs directed against cathepsin K and sclerostin as well as the new pathways of interest from preclinical studies. EXPERT OPINION: New scientific results have identified novel signaling pathways as potential targets for future development of anti-osteoporotic drugs. The treatments close to marketing at the moment are odanacatib and romosozumab and these are both promising new medications based on bone mineral density results, safety profile and administration. Theoretically, romosozumab may hold the potential to be a drug to 'cure' even advanced stages of osteoporosis with short-term treatment. However, safety, fracture data and cost are key elements that will determine the extent of use.
Expert Opinion on Drug Discovery, 2014, Vol 9, Issue 3, p. 245-253
Anabolic Agents; Animals; Antibodies, Monoclonal; Biphenyl Compounds; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Cathepsin K; Drug Design; Genetic Markers; Humans; Osteoporosis